À̹ÌÁö È®´ë Samsung Bioepis, an unlisted subsidiary of Samsung Biologics, generated $542 million from sales of its three biosimilars in Europe for the first nine months of this year, topping last year¡¯s full revenue and triggering jump in the stock price of its Korean parent.
According to the earnings report of Biogen on Tuesday (local time), Samsung Bioepis` marketing partner in Europe, sales of its three biosimilar products – Benepali, Flixabi, and Imraldi -- totaled $183.6 million in the non-U.S. region in the third quarter, down a fraction from the previous quarter but up 36 percent from a year earlier.
Samsung Bioepis is a biosimilar-focused joint venture between Samsung BioLogics and U.S.-based Biogen. Samsung Biologics with slightly above 50 percent interest in the joint venture Wendesday gained 8.1 percent higher at 372,000 won ($27.3) on expectations for contribution to its bottom line.
À̹ÌÁö È®´ë Benepali (etanercept), Imraldi (adalimumab) and Flixabi (infliximab)
During the July-September period, Benepali (etanercept) sales reached $112 million while Flixabi (infliximab) generated $184 million. The sales of Imraldi (adalimumab), which was launched in October last year, came to $493 million.
The combined revenue of these three products in January-September this year are $542 million, or 99.5 percent of their full-year revenue a year ago.
Biogen said the three biosimilars have been prescribed to approximately 180,000 patients in Europe, and it expects to contribute up to ¢æ1.8 billion of healthcare savings in 2019.
By Kim Byung-ho and Minu Kim
[¨Ï Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]